What weight loss results does Wegovy 0.25 mg actually produce?

Why the 0.25 mg phase exists, according to the clinical evidence

The STEP 1 trial, published in the New England Journal of Medicine, randomised adults with obesity or overweight alongside a weight-related condition to semaglutide 2.4 mg or placebo over 68 weeks. Average weight loss at that maintenance dose was roughly 15%. What the headline figure does not tell you is that every participant in the semaglutide group started at exactly 0.25 mg — the same dose the question above asks about.

That starting dose was never designed to produce measurable fat loss. Its role is pharmacological housekeeping: easing the gut into GI stimulation, reducing the likelihood of nausea or vomiting that can derail treatment early. The prescribing guidance, reflected in the NHS medicines information for semaglutide, describes the 0.25 mg phase as a tolerability step lasting roughly four weeks before the first dose increase to 0.5 mg.

There is a common misconception that a lack of obvious results during the first month signals the medicine is not working. That is simply not how the escalation schedule is built. If you want to understand what people actually experience during this period, our page covering what to expect from 0.25 mg Wegovy results gives a detailed picture. The 0.25 mg phase is preparing your system for the doses that actually move the needle. Expecting 15% weight loss in week four is the wrong benchmark entirely.

What you are likely to notice (and what you probably will not) at 0.25 mg

Most people report only mild changes in appetite during the first four weeks. Some notice that portions feel slightly smaller before they feel full; others notice very little at all. Both experiences are normal. The GLP-1 receptor agonist mechanism (slowing gastric emptying and signalling fullness to the brain) becomes more pronounced at higher doses.

Side effects during the 0.25 mg phase tend to be the most prominent of the entire schedule, because the body is encountering the medicine for the first time. Nausea, mild bloating and occasional loose stools are the most frequently reported. For most people these settle within the first couple of weeks and are considerably less noticeable by the time the dose increases. If they do not settle, or are severe, that is exactly the kind of thing to discuss with your prescriber, not something to work through alone.

Weight on the scale may change very little, or not at all, in this phase. That is the expected picture. Understanding how the full Wegovy dose schedule is structured helps put the 0.25 mg phase in proportion: it is the first step on a staircase, not the landing.

Results across the escalation schedule: what the progression looks like

After 0.25 mg, the licensed escalation moves to 0.5 mg, then 1.0 mg, then 1.7 mg, and finally to the 2.4 mg maintenance dose, each step roughly four weeks apart, guided by the prescriber. Our page on Wegovy 0.5 mg results sets out what most people notice at that second dose, where appetite suppression typically starts to become clearer. Results at 0.5 mg tend to be modest but more noticeable than at the starting dose; appetite suppression becomes clearer for most people from around the 1 mg phase onward.

By the time participants in STEP 1 reached and stayed at 2.4 mg, the average weight reduction was around 15% of starting body weight at 68 weeks. Some participants lost considerably more; some less. The variation is real, and no prescriber can predict where an individual will land. What the trial confirms is that the journey to those results runs through 0.25 mg, it does not start at 0.25 mg.

For context on the higher end of what semaglutide can achieve, the newer 7.2 mg dose (approved by the MHRA in 2026) reported average weight loss of around 20.7% over 72 weeks in trials. That ceiling matters less during the 0.25 mg phase than understanding the trajectory: slow start, steady build, meaningful results over months not weeks. You can read more about the results seen at the 2.4 mg maintenance dose to understand what the endpoint evidence looks like.

How a prescriber's oversight shapes what happens at each dose

Dose decisions are not automatic. A prescriber reviews how you are tolerating the current dose before agreeing a step up. That conversation matters: someone experiencing persistent nausea might stay at 0.25 mg or 0.5 mg longer than four weeks, and that is clinically sound, not a failure. Someone tolerating the starting dose well might move through the early phases without drama.

This is one reason the Wegovy treatment overview stresses that clinical oversight is built into every repeat, not just the first prescription. At nume, a GPhC-registered prescriber reads your case before each new supply, a real clinician, not an automated system. If you are thinking about whether semaglutide might be appropriate for you, the consultation on our weight-loss treatments page is the place to start.

Private Wegovy treatment involves one transparent cost covering consultation, prescription, delivery and ongoing clinical support. For an honest account of what that looks like, our weight-loss treatment guide covers cost context alongside eligibility. Check your eligibility at any point and speak to our prescribers about whether semaglutide is the right route for you.